Determination of appropriate dosing of influenza drugs in pediatric patients

Clinical Pharmacology and Therapeutics

Volumn 88, Issue 5, 2010, Pages 704-707

  Acosta, E P ^a,b   Kimberlin, D W ^b  

^a The Purdue Univ Univ of Alabama at Birmingham Botanical Center for Age Related Disease   (United States)

^b University of Alabama at Birmingham and Children's Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANTIVIRUS AGENT; CYTOCHROME P450; EFAVIRENZ; GLUCURONOSYLTRANSFERASE; OSELTAMIVIR; PERAMIVIR; RIMANTADINE; VALGANCICLOVIR; ZANAMIVIR;

ANTIVIRAL THERAPY; AREA UNDER THE CURVE; CONCENTRATION RESPONSE; CYTOMEGALOVIRUS INFECTION; DRUG ABSORPTION; DRUG DISPOSITION; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG PROTEIN BINDING; HIGH RISK POPULATION; HOSPITALIZED CHILD; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLUENZA; INFLUENZA VIRUS; PREMATURITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; VIRUS STRAIN; AGE; BIOLOGICAL MODEL; COMPUTER SIMULATION; DOSE CALCULATION; DOSE RESPONSE; DRUG ADMINISTRATION; INFANT; INFLUENZA, HUMAN; METABOLISM; NEWBORN; TREATMENT OUTCOME;

AGE FACTORS; ANTIVIRAL AGENTS; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG DOSAGE CALCULATIONS; HUMANS; INFANT; INFANT, NEWBORN; INFANT, PREMATURE; INFLUENZA, HUMAN; MODELS, BIOLOGICAL; TREATMENT OUTCOME;

EID: 77958480796     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.173     Document Type: Review

References (21)

1. Bhat, N. et al. Infuenza-associated deaths among children in the United States, 2003-2004. N. Engl. J. Med. 353, 2559-2567 (2005).
2. Izurieta, H.S. et al. Infuenza and the rates of hospitalization for respiratory disease among infants and young children. N. Engl. J. Med. 342, 232-239 (2000).
3. Neuzil, K.M., Mellen, B.G., Wright, P.F., Mitchel, E.F. Jr & Grifn, M.R. The efect of infuenza on hospitalizations, outpatient visits, and courses of antibiotics in children. N. Engl. J. Med. 342, 225-231 (2000).
4. Iwane, M.K. et al. Population-based surveillance for hospitalizations associated with respiratory syncytial virus, infuenza virus, and parainfuenza viruses among young children. Pediatrics 113, 1758-1764 (2004).
5. O'Brien, M.A. et al. Incidence of outpatient visits and hospitalizations related to infuenza in infants and young children. Pediatrics 113, 585-593 (2004).
6. Kearns, G.L., Abdel-Rahman, S.M., Alander, S.W., Blowey, D.L., Leeder, J.S. & Kaufman, R.E. Developmental pharmacology-drug disposition, action, and therapy in infants and children. N. Engl. J. Med. 349, 1157-1167 (2003).
7. Hall, S.D. et al. Molecular and physical mechanisms of frst-pass extraction. Drug Metab. Dispos. 27, 161-166 (1999).
8. Efavirenz (Sustiva) [package insert]. Princeton, NJ: Bristol-Myers Squibb, 2010.
9. Marzolini, C., Telenti, A., Decosterd, L.A., Greub, G., Biollaz, J. & Buclin, T. Efavirenz plasma levels can predict treatment failure and central nervous system side efects in HIV-1-infected patients. AIDS 15, 71-75 (2001). (Pubitemid 32055781)
10. Oseltamivir (Tamifu) [package insert]. Nutley, NJ: Roche Laboratories, 2008.
11. Kimberlin, D.W. et al. Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus disease. J. Infect. Dis. 197, 836-845 (2008).
12. Acosta, E.P. et al. Ganciclovir population pharmacokinetics in neonates following intravenous administration of ganciclovir and oral administration of a liquid valganciclovir formulation. Clin. Pharmacol. Ther. 81, 867-872 (2007).
13. Kimberlin, D. et al. Oseltamivir (OST) and OST carboxylate (CBX) pharmacokinetics (PK) in infants: interim results from a multicenter trial [abstr. 1041]. 47th Annual Meeting of the Infectious Diseases Society of America, Philadelphia, PA, 31 October 2009.
14. Zanamivir (Relenza) [package insert]. Research Triangle Park, NC: GlaxoSmithKline, 2008.
15. Acosta, E.P. et al. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Oseltamivir dosing for infuenza infection in premature neonates. J. Infect. Dis. 202, 563-566 (2010).
16. Anderson, B.J. & Holford, N.H. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu. Rev. Pharmacol. Toxicol. 48, 303-332 (2008).
17. Rhodin, M.M. et al. Human renal function maturation: a quantitative description using weight and postmenstrual age. Pediatr. Nephrol. 24, 67-76 (2009).
18. D'Argenio, D.Z., Schumitzky, A & Wang, X. ADAPT 5 User's Guide: Pharmacokinetic/Pharmacodynamic Systems Analysis Software (Biomedical Simulations Resource, Los Angeles, CA, 2009).
19. American Academy of Pediatrics. Infuenza. In Red Book: 2009 Report of the Committee on Infectious Diseases 28th edn. (eds. Pickering, L.K., Baker, C.J., Long, S.S. & Kimberlin, D.W.) 400-412 (Elk Grove Village, IL: American Academy of Pediatrics, 2009).
20. Oseltamivir (Tamifu) [package insert]. Nutley, NJ: Roche Laboratories, 2010.
21. US Centers for Disease Control and Prevention. Peramivir Emergency Use Authorization. Fact Sheet for Health Care Professionals (2009)